Breviprost

Breviprost is a preservative-free ophthalmic formulation of travoprost, a synthetic prostaglandin F2α analogue, developed and manufactured by Liqvor. It is approved for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. As a selective agonist of the prostaglandin F receptor (PTGFR), travoprost lowers intraocular pressure by increasing the outflow of aqueous humor, primarily via the uveoscleral pathway. The preservative-free formulation of Breviprost is designed to minimize corneal toxicity, ocular irritation, and the development of dry eye syndrome, which are common with long-term use of preserved eye drops.

Brand names

Breviprost

Other names

Breviprost preservative-freetravoprost